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Abstract
Trust may be important in shaping public attitudes to genetics and intentions to participate in genomics research and big data 
initiatives. As such, we examined trust in data sharing among the general public. A cross-sectional online survey collected 
responses from representative publics in the USA, Canada, UK and Australia (n = 8967). Participants were most likely to 
trust their medical doctor and less likely to trust other entities named. Company researchers were least likely to be trusted. 
Low, Variable and High Trust classes were defined using latent class analysis. Members of the High Trust class were more 
likely to be under 50 years, male, with children, hold religious beliefs, have personal experience of genetics and be from the 
USA. They were most likely to be willing to donate their genomic and health data for clinical and research uses. The Low 
Trust class were less reassured than other respondents by laws preventing exploitation of donated information. Variation in 
trust, its relation to areas of concern about the use of genomic data and potential of legislation are considered. These findings 
have relevance for efforts to expand genomic medicine and data sharing beyond those with personal experience of genetics 
or research participants.
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Introduction
The future of genomic medicine and research relies upon the 
sharing of health and genomic data to facilitate large-scale 
analyses and support clinical interpretation of genetic variants 
(ACMG Board of Directors 2017; Raza and Hall 2017). There 
is scientific and policy support for data sharing, and efforts 
are ongoing to develop technical, ethical and legal solutions 
to connect genomic databases and make them more accessi-
ble for clinical and research purposes (Kaye et al. 2009; Siu 
et al. 2016; Birney et al. 2017; Borry et al. 2018). In addition, 
sharing genomic data relies on the support and involvement of 
members of the public from whom data are collected—whether 
as patients or research volunteers (Nuffield Council on Bio-
ethics 2015; Kaye et al. 2018). In this context, the notion of 
trust is particularly important (Trinidad et al. 2010; Eckstein 
et al. 2018; Lawler et al. 2018). Trust relates to the ability of 
researchers, institutions and governance arrangements to real-
ise benefits and manage or mitigate risks associated with data 
sharing, including to privacy and confidentiality (Shabani et al. 
2014; Nuffield Council on Bioethics 2015). It can be conceptu-
alised as a heuristic that is activated when people are faced with 
risks and need to make decisions or a ‘leap of faith’ with little 
or no available information (Luhmann 2000; Mollering 2001; 
Lipworth et al. 2009).
Trust is consistently identified as an important factor both 
shaping attitudes to genomics and the intentions of members of 
the public to participate in genomics research and big data ini-
tiatives (Lipworth et al. 2009; Critchley et al. 2015; Nicol et al. 
2016; Lawler et al. 2018). Conversely, the failure of the UK’s 
clinical data sharing initiative, care.data, has been partly attrib-
uted to a failure to obtain public trust (van Staa et al. 2016). 
Lack of trust in the initiative seems to be related to concerns 
about transparency in the use of data, respect for confidentiality 
and privacy and commercialisation (Sterckx et al. 2016). Where 
trust is absent, the social licence and mandate of researchers 
and clinicians to obtain and distribute data may be lost (Carter 
et al. 2015).
The collection and subsequent sharing of genomic data 
involves a range of actors, including individual doctors, health 
services and public sector or university-based researchers. Max-
imising the benefits from genomic medicine is also likely to 
require the involvement of commercial actors and governments 
as users, providers and/or regulators of data. Previous research 
suggests that the involvement of companies as users of genomic 
and health data may present concerns for data donors (Caul-
field et al. 2014; Ipsos MORI 2016). However, there is little 
evidence on the prevalence of such concerns across national 
contexts, how members of the public discriminate between 
actors and how this relates to people’s willingness to donate 
their genomic and health data. Further, existing research sug-
gests that ‘the public’ who are donating data and samples for 
genomic research are by no means a homogeneous group, and 
that responsible engagement should reflect the diverse groups 
which make up the donating public (Hoeyer 2010; Gaskell et al. 
2013; Ipsos MORI 2016).
In this paper, we examine trust in data sharing among 
the general public, drawing from a representative sample 
of 8967 English-speaking members of the public from the 
UK, the USA, Canada and Australia. We explore levels of 
trust in the individual and organisational actors involved in 
the collection and sharing of genomic and health data. We 
identify subgroups within this large sample and examine 
the relationship between patterns of trust associated with 
these groups, demographic characteristics, including age, 
sex, educational level and religiosity, and experiences and 
expectations related to data. These include the willingness to 
donate data, experience of data breaches, concerns related to 
commercial and governmental use, and the perceived value 
of legal or regulatory action related to data governance.
Methods
The findings presented are part of the ‘Your DNA, Your 
Say’ global online survey of public perceptions and values 
towards donating DNA and health data. Detailed methodo-
logical rationale for the study, design (and limitations), 
recruitment strategy and process of data collection have 
been published separately (Middleton 2018; Middleton 
et al. 2018b).
Sample
Respondents were randomly recruited by email invite 
through the market research company Dynata, which 
adheres to the ESOMAR market research code of con-
duct. We collected completed surveys in the USA, Canada, 
United Kingdom (UK) and Australia (n = 8967). Partici-
pants were paid a small financial reward (< £1) for partici-
pating and due to the nature of recruitment there are no 
details on non-response rate. Respondents were recruited 
from Dynata’s nationally representative research panel in 
each country. However, the variables we collected within 
the study were oriented towards enabling comparison 
between countries. There is variability in how ethnicity 
and education data are collected between countries, while 
national levels of income also vary. Consequently, age and 
gender were retained as the two primary criteria on which 
we could match the YDYS population to census data (see 
Supplementary Material). Where sections of the popula-
tion were under-represented, Dynata contacted additional 
respondents to more closely approximate census data.
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Measures
The cross-sectional, exploratory online survey can be 
accessed at www.YourD NAYou rSay.org. It contains 29 
questions and piloting showed it took approximately 
15–20 min to complete.
Familiarity with DNA, genetics and genomics
Familiarity was ascertained based on two questions: “Are 
you familiar with DNA, genetics or genomics?” and “I’m 
familiar through my work, personal interests or family/
medical history”. Participants were categorised as hav-
ing “Personal” experience of genetics if they were famil-
iar with DNA/genetics/genomics due to either having a 
genetic condition in their family, or through their work 
(e.g. genetic health professional or genetic researcher).
Trust in individuals and organisations
Participants were asked to identify what factors would influ-
ence their decision to donate their DNA and medical infor-
mation. They were asked to indicate if they would trust the 
people below (multiple selections possible):
• My medical doctor.
• Any medical doctor in my country.
• Any researcher at a university in my country.
• Any researcher in a company in my country.
• The government of my country.
Response options were “I would generally trust”, “I’m 
just not sure” and “I would not generally trust”. These cat-
egories were used for descriptive analyses, with the latter 
two combined for the multivariable analyses. This distin-
guishes between those who have made a positive judgement 
about the trustworthiness of the entities concerned and oth-
ers, reflecting our theoretical understanding of trust as an 
active ‘leap of faith’.
Donating DNA and medical information
Throughout the survey, participants were asked whether 
they would donate their “anonymous’’1 DNA and medical 
information for use by others. We asked participants to dis-
tinguish who they would allow to use their data, (a) medical 
doctors; (b) non-profit researchers; (c) for-profit research-
ers. Participants were classified as willing to donate if they 
answered “yes” to at least one of these questions, unwill-
ing to donate if they answered “no” to all three, and unsure 
if they answered “unsure” to all three. This classification 
aimed to identify people who would be willing to donate in 
at least some circumstance.
Negative experiences online
To determine whether participants had experienced negative 
consequences relating to online access to personal informa-
tion we asked: “Websites have variable levels of security. 
Have you had any negative experiences from your personal 
information being accessed online?”. Possible responses 
were “Yes”, “No”, “I’m not sure”. The latter two categories 
were collapsed for analysis purposes.
Concerns about specific harms
Participants were presented with a list of hypothetical harms 
that could occur as a result of their DNA information being 
accessed by others, and asked to indicate how concerned 
they felt about each of these (“Not bothered”, “Concerned”, 
“Very concerned”, “I’m not sure”). The list of hypotheti-
cal harms was based on pilot work, the academic literature 
and the experience of the authors who designed the survey. 
The full list has been described previously; for this research 
we focused on the following concerns that were considered 
relevant to trust in different organisations involved in using 
DNA and health data (Middleton et al. 2018a):
• My government potentially knowing something about me 
that I hadn’t chosen to tell them.
• Police potentially knowing something about me that I 
hadn’t chosen to tell them.
• Marketing companies targeting me to sell me products.
• Health or life insurance companies using the information 
to discriminate against me.
For analyses of these measures, the four categories of 
concern were collapsed into two; “Concerned” was com-
bined with “Very concerned”, and “Not bothered” with “I’m 
not sure” to capture the existence of definite concerns,.
Influence of regulation on views of donation
Participants were asked “Would you be more comfortable 
donating your DNA and/or medical information if you knew 
there was a law in place to protect against being exploited?” 
1 Here we mean ‘de-identified’, but pilot work showed that ‘anony-
mous’ was more easily understood by participants. A glossary defi-
nition within the survey explained ‘anonymous’ as: ‘removal of per-
sonal information such as name and date of birth. It is questionable 
as to whether DNA information can ever be truly anonymous as our 
DNA code is unique to us and thus, in itself, could be used to identify 
us. However, in the circumstances we are exploring here, by making 
DNA and medical information ’anonymous’, we mean detaching per-
sonal identifiers from it.’.
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with options “Yes”, “No”, “I’m not sure”. The latter two 
categories were collapsed for analysis.
Socio‑demographics
Age was collected in 10-year categories from age 16 years 
onwards, but due to the lower number of responses in 
younger and older age categories, these were collapsed into 
three categories of “30 years and under”, “31–50 years” and 
“51 years and older” for analysis. Whether participants had 
children was determined by a “Yes” or “No” answer without 
specifying whether the children were biological or not. Rela-
tionship status was collected as “Divorced”, “Separated”, 
“Single”, “Widowed”, “Married/civil partnership/living 
together”, but all categories apart from the latter were col-
lapsed for analyses.
We piloted how to collect ethnicity data, starting with 
the categories provided by the World Health Organization 
and the UK Office for National Statistics and adapting these 
based on feedback from pilot participants involved in survey 
development. The resultant ethnicity question in the final 
survey thus asked participants to self-identify as: white; 
Afro-European/African American, black; Hispanic; South 
Asian, Indian, Pakistani; East Asian Chinese, Japanese; Ara-
bic, Central Asian; Other. Participants could also choose 
not to answer this question at all. In the analysis, due to low 
number of participants who self-identified as a member of 
a group other than “White” (less than 10% of the sample 
for each country), these were collapsed into a single “Non-
White” category for analysis.
Highest level of education was categorised as “Tertiary”, 
“Secondary”, “Primary” or “Other” based on structured 
responses and also free-text descriptions of educational qual-
ifications. This was collapsed to a binary indicator of tertiary 
education (vs no tertiary education) for multivariable analy-
ses. Religiosity was determined by participants’ responses to 
the question “Independent of whether you attend religious 
services or not, would you say you are…?” with options “A 
religious person” or “Not a religious person”.
Statistical analysis
Latent class analysis (LCA) identifies subgroups, or latent 
classes, within a sample using the pattern of respondents’ 
scores on the five trust variables. The aim is not to rep-
resent all possible combinations of characteristics, but to 
identify the main patterns present, assuming some measure-
ment error (Lanza and Rhoades 2013; Lanza et al. 2013). 
In this case, the use of LCA aims to identify the number of 
groups that demonstrate distinct patterns of scores across 
the trust variables. To find the likely number of subgroups, 
models postulating increasing numbers of latent classes 
were sequentially fitted. Identification of each model was 
evaluated by refitting it using 100 sets of random starting 
values and inspecting the percentage that converged to the 
same solution (Lanza and Rhoades 2013; Lanza et al. 2013). 
The best-fitting model was selected by examining the Akaike 
information criterion (AIC), Bayesian information criterion 
(BIC) and entropy for each model and considering the size, 
distinctness and ease of interpretation of the classes identi-
fied (Nylund et al. 2007). This was informed by the class 
membership probabilities, the estimated proportion of the 
sample belonging to each class and the item-response prob-
abilities for each class, which represent the likely values for 
the set of characteristics (i.e. probability of trusting each 
individual/organisation), given membership of a particular 
class.
Multinomial logistic regression models estimated via 
the ‘one-step’ approach were used to explore associations 
between individual covariates and subgroup membership 
(Feingold et al. 2013). Coefficient estimates for each class 
were combined with the known distribution of each covari-
ate to estimate the probability of each covariate value con-
ditional on latent class membership.
Models including adjustment for country of residence 
were fitted to examine the adjusted associations between 
class membership and (1) donating DNA and medical 
information; (2) knowledge of genetics; (3) negative 
experiences online; (4) concerns regarding use of DNA 
and medical information; (5) view on regulation and 
donation. All tests were two-tailed but given the number 
of models fitted, α = 0.05 was not appropriate. A Bonfer-
roni corrected threshold would be P ≤ 0.007, although we 
present and interpret P values as measures of the strength 
of evidence for an association rather than simply applying 
a threshold for statistical significance (Greenland et al. 
2016). Analyses were conducted in R (version 3.5.2) 
using the poLCA package (Linzer and Lewis 2011; R 
Core Team 2016).
Results
Sample characteristics
The total sample consisted of 8967 participants from the 
UK, USA, Canada and Australia. The socio-demographic 
characteristics of the sample are described in detail else-
where, but are provided in Supplementary Table S1 for com-
pleteness (Middleton et al. 2018a).
Overall, participants were most likely to trust their medi-
cal doctor (see Table 1). Participants were less likely to trust 
the other individuals/organisations named, with researchers 
at a company being the individuals least likely to be trusted. 
There were limited missing data in the data set; 97% of the 
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sample (n = 8659) were included in the complete case data 
set for the LCA.
Latent class analysis of trust in individuals 
and organisations
Five latent class models (one to five classes) were fitted, 
although fit statistics did not unequivocally identify a best-
fitting model (Supplementary Table S2). This discordance is 
not uncommon as the AIC and BIC have different strengths, 
despite the BIC generally selecting more parsimonious mod-
els and performing better for model selection in LCA of 
large samples (Nylund et al. 2007). The AIC was lowest for 
the five-class model, while the BIC was lowest for the four-
class model, but both models potentially had identification 
problems (Supplementary Figure S1). The three-class model 
appeared to represent the best trade-off between AIC, BIC 
and entropy fit indices. Examination of the item-response 
probabilities confirmed that the subgroups identified in the 
three-class model had distinct characteristics (Fig. 1 and 
Supplementary Table S3), and that no class was too small 
(the smallest class contained 16% of the sample, approxi-
mately 1386 participants). These results indicated that the 
three-class model was most appropriate for these data.
The item-response probabilities (Fig. 1) suggest that the 
classes defined by the three-class model can be characterised 
as follows:
• Low overall trust (41% of the sample): Moderate trust in 
own medical doctor and no trust in any other individuals/
organisations.
• Variable trust (43% of the sample): High levels of trust 
in medical professionals, moderate trust in university 
researchers and low trust in company researchers and 
own government.
• High overall trust (16% of the sample): High levels of 
trust in all individuals/organisations.
Latent class characteristics
Participants in the Variable Trust class were more likely to 
be from the UK, while those in the High Trust class were 
more likely to be from the USA (see Table 2). Gender also 
appeared to differ across with classes, with the High Trust 
class members more likely to be male compared to the other 
two classes (0.63 compared to 0.5 for the Variable Trust 
class and 0.48 for the Low Trust class), and less likely to 
Table 1  Number and percentage 
of participants expressing trust 
in doctors, researchers and 
government
Variable Categories Total no. Total perc.
My medical doctor No/unsure 2232 24.9
Yes 6727 75
Missing 8 0.1
Any medical doctor in my country No/unsure 5393 60.1
Yes 3562 39.7
Missing 12 0.1
Any researcher at a university in my country No/unsure 5899 65.8
Yes 3060 34.1
Missing 8 0.1
Any researcher at a company in my country No/unsure 7768 86.6
Yes 1192 13.3
Missing 7 0.1
The government of my country No/unsure 7251 80.9
Yes 1709 19.1
Missing 7 0.1
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Fig. 1  Item response probabilities for the 3-class model. Categories: 
myDoctor, my medical doctor; anyDoctor, any medical doctor in my 
country; anyUniversity, any researcher at a university in my country; 
anyCompany, any researcher at a company in my country; myGovt, 
the government of my country
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be over 50 (0.25 compared to 0.39 and 0.37). Those in the 
High Trust class were also more likely to have children (0.66 
compared to 0.57 and 0.56) and to be more educated (they 
were less likely not to have a tertiary-level education, 0.33 
compared to 0.42 and 0.47). Participants in the High Trust 
class were also substantially more likely to view themselves 
as a religious person (0.51 compared to 0.30 for the Vari-
able Trust class and 0.39 for the Low Trust class). The Low 
Trust class were more likely to be divorced, single or wid-
owed (0.42 compared to 0.36 of the Variable Trust class and 
0.32 of the High Trust class). The High Trust class were the 
most likely to have personal experience of genetics (0.27 
compared to 0.12 for the Variable Trust class and 0.09 for 
the Low Trust class). They were also slightly more likely 
to report being familiar with genetics (0.39 compared to 
0.31 and 0.28 for the Variable Trust and Low Trust classes, 
respectively).
Associations with latent class membership
Based on the multinomial logistic regression model, 
adjusted for country of residence, willingness to donate 
DNA and medical information was most strongly associ-
ated with membership of the High Trust class (OR 22.5, 95% 
CI 15.5–32.5; see Table 3), although there was also a strong 
association with the Variable Trust class (OR 6.2, 95% CI 
Table 2  Probability of 
characteristics related to 
demographics and knowledge 
of genetics given latent class 
membership
Variable Category Low trust Variable trust High trust
Country of residence UK 0.33 0.48 0.26
USA 0.25 0.14 0.35
Canada 0.26 0.24 0.24
Australia 0.16 0.14 0.15
Age Over 50 0.39 0.37 0.25
31–50 0.4 0.38 0.49
30 and under 0.21 0.25 0.26
Gender Male 0.5 0.48 0.63
Children Yes 0.56 0.57 0.66
Tertiary eduction No 0.47 0.42 0.33
Ethnicity Non-white 0.18 0.1 0.16
Religiosity A religious person 0.39 0.3 0.51
Relationship Divorced/single/widowed 0.42 0.36 0.32
Genetics knowledge Unfamiliar 0.63 0.57 0.34
Familiar 0.28 0.31 0.39
Personal 0.09 0.12 0.27
Table 3  Multinomial 
logistic regression result for 
associations of latent class 
membership with willingness 
to donate, and experiences and 
concerns related to data use
Variable Category Latent class
Variable trust High trust
Donation Unwilling Ref. Ref.
Willing 6.19 (5.16–7.43) < 0.0001 22.47 (15.53–32.51) < 0.0001
Unsure 1.51 (1.22–1.86) 0.02 1.64 (1.02–2.62) 0.12
Negative experience online No/unsure Ref. Ref.
Yes 0.67 (0.56–0.81) 0.006 3.07 (2.63–3.59) < 0.0001
Concern—government No/unsure Ref. Ref.
Yes 1 (0.87–1.14) 0.95 0.51 (0.44–0.58) < 0.0001
Concern—police No/unsure Ref. Ref.
Yes 0.74 (0.65–0.84) 0.003 0.63 (0.55–0.72) 0.001
Concern—marketing No/unsure Ref. Ref.
Yes 1.94 (1.63–2.3) < 0.0001 0.72 (0.62–0.84) 0.006
Concern—insurance No/unsure Ref. Ref.
Yes 1.79 (1.51–2.12) 0.001 0.74 (0.63–0.88) 0.012
Laws around donation No/unsure Ref. ref.
Yes 6.61 (5.7–7.66) < 0.0001 16.18 (13.25–19.77) < 0.0001
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5.2–7.4). Being unsure about donating was not associated 
with a particular class. The association between having had 
a negative experience online and trust profile varied sub-
stantially. Interestingly, a negative experience was associ-
ated with reduced odds of membership of the Variable Trust 
class (OR 0.67, 95% CI 0.56–0.81), but increased odds of 
belonging to the High Trust class (OR 3.1, 95% CI 2.6–3.6).
Participants who expressed concern about the govern-
ment knowing something about them if their DNA was 
linked to other personal information had substantially lower 
odds of belonging to the High Trust class (OR 0.51, 95% 
CI 0.44–0.58), but this concern did not distinguish between 
members of the Variable Trust and Low Trust classes. Par-
ticipants who were concerned about police use of this infor-
mation had much lower odds of belonging to the Variable 
Trust or High Trust classes (OR 0.75, 95% CI 0.65–0.84 and 
OR 0.63, 95% CI 0.55–0.72 respectively). Concern regard-
ing the use of this information for marketing or insurance 
purposes was associated with much greater odds of belong-
ing to the Variable Trust class (OR 1.96, 95% CI 1.63–2.3 
and OR 1.79, 95% CI 1.51–2.12 respectively) and somewhat 
lower odds of belonging to the High Trust class (OR 0.72, 
95% CI 0.62–0.84 and OR 0.74, 95% CI 0.63–0.88). Feeling 
reassured by laws preventing exploitation of donated infor-
mation was associated with much greater odds of belonging 
to the Variable Trust and High Trust classes (OR 6.61, 95% 
CI 5.7–7.7 and OR 16.2, 95% CI 13.3–19.8 respectively).
Discussion
Overall, the extent to which respondents trust different actors 
with their genomic and health data varies. Trust is strong-
est in individuals’ own doctors and lowest for other actors, 
particularly for companies and governments. These differ-
ences are consistent with other studies of public attitudes 
to commercial and government use of health and genomic 
data across the countries investigated here (Caulfield et al. 
2014; Critchley et al. 2015; Ipsos MORI 2016; Garrison 
et al. 2016). They reaffirm the importance of trust in doctors 
and the gatekeeping role played by individual’s own doctors 
in supporting the development of large-scale data sharing 
initiatives (Kelly et al. 2015). It presents challenges and sug-
gests the need to support dialogue about the role of research 
partnerships between public and private sectors.
The public are often seen as supportive of biomedical 
research and trusting of those who conduct it (Lipworth et al. 
2009). However, concerns about public trust reflect a percep-
tion that the public are potentially distrustful of many of the 
actors involved in data sharing. Our analysis suggests that 
as we build societal conversations about the sharing and use 
of genomic data, it is important to recognise that the gen-
eral public is not a uniform group with congruent interests 
(Resnik 2011; Caulfield et al. 2014). We have identified 
three subgroups characterised by their level of trust across 
the actors presented. Further, we have described differences 
in how these groups approach questions of data donation 
and sharing.
We identified a large group of the public who do not trust 
any group other than their own doctor with their DNA or 
health data. This distrustful, or at least sceptical, population 
represents a challenge for efforts to establish the trustwor-
thiness of entities involved in genomic data sharing. Typi-
cally, membership of this subgroup is associated with lower 
levels of willingness to donate data and increased odds of 
concern about the use or misuse of DNA data by police and 
governments. Membership of this group overlaps in terms 
of age, education and having children with those who are 
unwilling to donate their data (Middleton et al. 2018a). The 
low numbers of respondents from non-white ethnic groups 
limits the ability to identify differences related to ethnicity 
between Low Trust and the High and Variable Trust groups. 
There may be value of further exploration of the relationship 
between trust and donation across population subgroups.
Membership of the Variable Trust class was also associ-
ated with greater concern about government use of data, 
reflecting a shared lack of trust in government across these 
subgroups. Moreover, members of the Variable Trust group 
were also more concerned about the use of DNA or health 
data for insurance and marketing purposes, reflecting their 
lower level of trust in companies. It seems that, while legal 
reforms to address data sharing and the exploitation of 
donated information had little value for the low trust group, 
such laws appear to be more reassuring for the variable trust 
group. This suggests the potential for regulation to increase 
trust in data sharing among a sizeable subgroup of the popu-
lation, but also that the efficacy of such approaches depends 
on prior confidence in the ability of actors to manage risks 
to data donors. Such findings align with those studies that 
find that trust in science is greater among those with trust 
in other national institutions (Wellcome Trust 2019). This 
group, then, might be characterised as adopting a position 
of critical trust, in which a reliance on institutions to govern 
data sharing and use data responsibly is combined with a 
critical evaluation of their ability to do so (Walls et al. 2004).
Echoing previous findings, we find that membership of 
the High Trust subgroup is strongly associated with greater 
willingness to donate DNA and health data (Tomlinson 
et al. 2015). This group is more likely to be under 50 years, 
male, have children, hold religious beliefs, be from the USA 
and have a tertiary education and less likely to be single, 
divorced or widowed. They are also more likely to have per-
sonal familiarity with genetics, echoing previous findings 
that those who interact most frequently with health services 
are those most likely to support data sharing, including with 
the private sector (Ipsos MORI 2016). Previous work on 
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genetics has also suggested that men may be more accepting 
of genetic technologies and to perceive fewer risks (Connor 
and Siegrist 2010). This subgroup is more likely to have 
trust in individuals and organisations and also to have wider 
confidence in systems to manage and mitigate risks associ-
ated with sharing genomic data, as suggested by the much 
greater odds of this group supporting the value of laws to 
protect their data (Luhmann 2000). The characteristics of 
this group might also be indicative of an association between 
greater levels of social capital, in terms of the perceived 
agency of individuals in society and their connectedness to 
social organisations, and trust. The finding that this pop-
ulation comprises also those who are most likely to have 
had negative experiences related to access of their personal 
information data online may point to the resilience of sys-
temic confidence in this group—and a greater willingness to 
take the risky ‘leap of faith’ associated with trusting in data 
sharing arrangements.
Limitations
Exploratory cross-sectional online surveys have limita-
tions in that they capture an attitude or perception about 
intended behaviour at a single time point. While attitudes 
are a useful guide to behaviour, they may not directly 
translate. Hence, there is some evidence that people are 
more restrictive in hypothetical data sharing choices than 
those they adopt in practice (Oliver et al. 2012).
Overall limitations of the study and design have been 
published separately (Middleton et al. 2018c). Our results 
do not represent all English-speaking people around the 
world, nor should our findings be extrapolated to indicate 
views of all people from the USA, Canada, the UK and 
Australia. The survey was not designed to test a particular 
approach to supporting the development of public trust, 
but to generate hypotheses related to the perceptions and 
characteristics of the public as they relate to genomic data 
sharing. The cross-sectional data presented here suggest 
potentially interesting relationships between previous 
experiences of data-related problems and trust, and in the 
ability of regulation to modify trust in genomic data shar-
ing. Further work might explore whether this is affected 
by the provision of detail on how legal protections work. 
Future research might also investigate the relationship 
between data controversies and trust over time, and how it 
is affected by shifts in regulatory landscapes, including the 
EU General Data Protection Regulation.
Conclusions
This analysis adds to our understanding of how and to 
whom public trust is given in genomic data sharing. It 
reinforces the importance of acknowledging and being 
transparent about different users of genomic and health 
data, and of building on individual interpersonal relation-
ships of trust. By identifying different groups within the 
study population, the analysis contributes to understanding 
how trust varies, how this relates to specific areas of con-
cern associated with the use of genomic data by different 
actors and the potential of legal reform to mitigate these 
concerns.
The study findings are particularly pertinent as genomic 
data sharing moves from a research-focussed enterprise to 
a wider societal endeavour. Whereas those members of the 
public involved in research may be those most trusting of 
researchers and clinicians, larger-scale efforts will inevita-
bly draw those who are more sceptical into contact with 
genomic data sharing. In such circumstances, it is valuable 
to recognise the diversity of trust, the limits of policy and 
legislative action in reinforcing trust; and to consider how to 
engage with ambivalence in building approaches to data col-
lection, sharing and use (Cunningham-Burley 2006). Finally, 
the study points to the importance of considering the range 
of social and cultural contexts within which data sharing 
occurs, as genomics enters the global clinical mainstream.
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